| 段洪波,袁春晓,刘晓龙.帕金森病病人血清 Sestrin2、sICAM-1水平与睡眠障碍的关系[J].安徽医药,2025,29(4):692-696. |
| 帕金森病病人血清 Sestrin2、sICAM-1水平与睡眠障碍的关系 |
| Serum levels of Sestrin2 and sICAM-1 in Parkinson's disease patients and their relationship with sleep disorders |
| |
| DOI：10.3969/j.issn.1009-6469.2025.04.011 |
| 中文关键词: 帕金森病 入睡和睡眠障碍 应激诱导蛋白 2 可溶性细胞间黏附分子 -1 超氧化物歧化酶 |
| 英文关键词: Parkinson's disease Sleep initiation and maintenance disorders Sestrin 2 Soluble intercellular adhesion molecule-1 Superoxidedismutase |
| 基金项目:河北省中医药管理局中医药类科研计划课题项目( 2021295) |
|
| 摘要点击次数: 242 |
| 全文下载次数: 152 |
| 中文摘要: |
| 目的分析帕金森病( PD)病人血清应激诱导蛋白 2(Sestrin2)、可溶性细胞间黏附分子 -1(sICAM-1)水平及其与睡眠障碍的关系。方法选取河北省沧州中西医结合医院 2020年 1月至 2023年 2月收治的 164例 PD病人，根据帕金森病睡眠量表(PDSS)评分划分为睡眠障碍组( 92例)和无睡眠障碍组( 72例)；酶联免疫吸附分析测定血清 Sestrin2、sICAM-1水平；比较睡眠障碍组、无睡眠障碍组 PD病人血清 Sestrin2、sICAM-1水平及一般资料。 Pearson法分析 Sestrin2与 sICAM-1水平相关性； Spear. man法分析 Sestrin2、sICAM-1水平与匹兹堡睡眠质量指数( PSQI)相关性； logistic回归分析影响 PD病人出现睡眠障碍的因素；受试者操作特征曲线( ROC曲线)分析血清 Sestrin2、sICAM-1水平对 PD病人出现睡眠障碍的预测价值。结果血清 Sestrin2、 sICAM-1水平睡眠障碍组［(11.73±1.67)μg/L、(2.66±0.37)μg/L］显著高于无睡眠障碍［(7.32±1.48)μg/L、(1.95±0.32)μg/L］(P <0.05)。睡眠障碍组 PD病人超氧化物歧化酶、精神状况检查( MMSE)评分、蒙特利尔认知评估量表( MoCA)评分［( 102.35±20.85)U/mL、(26.93±3.02)分、(26.54±3.17)分］显著低于无睡眠障碍组 PD病人［(128.16±20.92)U/mL、(28.12±3.05)分、(27.76±3.25)分］，且睡眠障碍组丙二醛、 PSQI显著高于无睡眠障碍组 PD病人( P<0.05)；相关性分析结果表明， Sestrin2与 sICAM-1水平呈正相关(r=0.60，P<0.001)；血清 Sestrin2、sICAM-1水平与超氧化物歧化酶呈负相关，与丙二醛、 PSQI呈正相关(P<0.05)； logistic回归分析结果显示，超氧化物歧化酶、丙二醛、 Sestrin2、sICAM-1为 PD病人出现睡眠障碍的影响因素(P<0.05)； ROC曲线结果表明， Sestrin2、sICAM-1水平联合预测 PD病人出现睡眠障碍的 AUC为 0.99，显著高于 Sestrin2(AUC=0.98)、sICAM-1(AUC=0.93)单独检测( ZSestrin2-联合 =2.01，P=0.044，ZsICAM-1-联合 =3.13，P=0.002)。结论 PD病人血清 Sestrin2、sICAM-1水平较高，二者均为 PD病人出现睡眠障碍的影响因素， Sestrin2、sICAM-1水平联合对预测 PD病人出现睡眠障碍具有较高价值。 |
| 英文摘要: |
| Objective To analyze the serum levels of Sestrin 2 and soluble intercellular adhesion molecule-1 (sICAM-1) in patients with Parkinson's disease (PD) and their relationship with sleep disorders.Methods A total of 164 PD patients admitted to Cangzhou Hospital of Integrated TCM-WM·Hebei from January 2020 to February 2023 were collected, and according to the Parkinson's diseasesleep scale (PDSS) score, they were grouped into a sleep disorder group (92 cases) and a non-sleep disorder group (72 cases), another 80 healthy individuals without sleep disorders were regarded as the control group; enzyme-linked immunosorbent assay was applied to measure serum levels of Sestrin2 and sICAM-1; the serum levels of Sestrin2 and sICAM-1, and general information were compared be. tween the sleep disorder group and the non-sleep disorder group. Pearson method was applied to analyze the correlation between Ses. trin2 and sICAM-1 levels; Spearman method was applied to analyze the correlation between the levels of Sestrin2 and sICAM-1 with Pittsburgh sleep quality index (PSQI); Logistic regression was applied to analyze the factors that affected the occurrence of sleep disor.ders in PD patients; ROC curve was applied to analyze the predictive value of serum Sestrin2 and sICAM-1 levels for sleep disorders in PD patients.Results The serum levels of Sestrin2 and sICAM-1 in the sleep disorder group [(11.73±1.67)μg/L, (2.66±0.37)μg/L] were significantly higher than those in non-sleep disorder group [(7.32±1.48)μg/L, (1.95±0.32)μg/L], and the differences were statistically significant (P<0.05). Malondialdehyde, the MMSE score and MoCA score of the sleep disorder group [(102.35±20.85) U/mL, (26.93±3.02) points, (26.54±3.17) points] were obviously lower than those of the non-sleep disorder group[(128.16±20.92) U/mL, (28.12±3.05)points, (27.76±3.25) points], while superoxide dismutase and the PSQI in sleep disorder group was obviously higher than that of the non sleep disorder group (P<0.05); the correlation analysis results showed a positive correlation between Sestrin2 and sICAM-1 levels (r= 0.60, P<0.001); the serum levels of Sestrin2 and sICAM-1 were negatively correlated with superoxide dismutase, and positively correlat. ed with malondialdehyde and PSQI (P<0.05); the results of Logistic regression analysis showed that superoxide dismutase, malondialde. hyde, Sestrin2 and sICAM-1 were the influencing factors for sleep disorders in PD patients (P<0.05); ROC curve results showed that the combined prediction of Sestrin2 and sICAM-1 levels for sleep disorders in PD patients had an AUC of 0.99, which was obviouslyhigher than that of Sestrin2 (AUC=0.98) and sICAM-1 (AUC=0.93) tested separately (ZSemin2-combination=2.01, P=0.044, ZsICAM-1-combination=3.13, P=0.002).Conclusion The serum levels of Sestrin2 and sICAM-1 are higher in PD patients, both of which are influencing factors for sleep disorders. The combination of Sestrin2 and sICAM-1 levels has high value in predicting sleep disorders in PD patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
